Agile Therapeutics was founded in 1997 and is headquartered in Princeton, US

President & CEO & Board ofDirectors

Chief Financial Officer

Vice President of Manufacturing

Chief Development Officer, Vice President, Operations

Senior Vice President and Chief Medical Officer

Agile Therapeutics has an office in Princeton

Princeton, US (HQ)

101 Poor Farm Rd

USD

## Net income (Q1, 2017) | (7.5 m) |

## EBIT (Q1, 2017) | (7.1 m) |

## Market capitalization (17-Aug-2017) | 100.2 m |

## Cash (31-Mar-2017) | 41.7 m |

Agile Therapeutics's current market capitalization is $100.2 m.

- Source: SEC Filings

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## R&D expense | 13.4 m | 25.6 m | 20.9 m |

## General and administrative expense | 5.2 m | 7.5 m | 8.8 m |

## Operating expense total | 18.5 m | 33.1 m | 29.7 m |

## EBIT | (18.5 m) | (33.1 m) | (29.7 m) |

## Interest expense | (1.6 m) | (2.1 m) | (2.4 m) |

## Interest income | 2.6 k | 5 k | 117 k |

## Net Income | (16.1 m) | (30.3 m) | (28.7 m) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## R&D expense | 2.4 m | 4.6 m | 5.4 m | 6.2 m | 7.2 m | 4.9 m | 5.6 m | 4.9 m | 4.7 m |

## General and administrative expense | 1.1 m | 1.4 m | 1.6 m | 1.8 m | 1.8 m | 2.1 m | 2.3 m | 2.2 m | 2.4 m |

## Operating expense total | 3.5 m | 6 m | 7 m | 8 m | 9 m | 7 m | 7.8 m | 7.1 m | 7.1 m |

## EBIT | (3.5 m) | (6 m) | (7 m) | (8 m) | (9 m) | (7 m) | (7.8 m) | (7.1 m) | (7.1 m) |

## Interest expense | (403.5 k) | (392 k) | (425.8 k) | (547.6 k) | (551.7 k) | (548 k) | (548 k) | (784 k) | (546 k) |

## Interest income | 82 | 1.3 k | 1.2 k | 1.3 k | 1.2 k | 17 k | 33 k | 33 k | 47 k |

## Net Income | (2.9 m) | (9.2 m) | (8.5 m) | (17 m) | (26.4 m) | (7.3 m) | (15.7 m) | (23.5 m) | (7.5 m) |

- Source: SEC Filings

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Cash | 40.2 m | 34.4 m | 48.8 m |

## Accounts Receivable | 539 m | ||

## Current Assets | 41 m | 38.1 m | 51.5 m |

## PP&E | 12 m | 12.3 m | 12.3 m |

## Total Assets | 54.8 m | 50.7 m | 63.9 m |

## Accounts Payable | 2.6 m | 2.4 m | 2.1 m |

## Current Liabilities | 9 m | 7.9 m | 10.7 m |

## Additional Paid-in Capital | 170.4 m | 194.5 m | 235.8 m |

## Retained Earnings | (134.4 m) | (164.7 m) | (193.5 m) |

## Total Equity | 36 m | 29.7 m | 42.3 m |

## Financial Leverage | 1.5 x | 1.7 x | 1.5 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 53.5 m | 45.7 m | 53.9 m | 46.4 m | 39.4 m | 65.5 m | 59.2 m | 51.7 m | 41.7 m |

## Current Assets | 54.2 m | 47 m | 54.4 m | 47.2 m | 40.7 m | 68.5 m | 61.3 m | 54.8 m | 44.3 m |

## PP&E | 12.3 m | 12.3 m | 12.3 m | 12.3 m | |||||

## Total Assets | 66.3 m | 60.9 m | 68.7 m | 61.7 m | 55.1 m | 80.9 m | 73.6 m | 67.1 m | 56.6 m |

## Accounts Payable | 2.3 m | 2.7 m | 3.3 m | 2.7 m | 4.3 m | 2.9 m | 3 m | 2.9 m | 3.2 m |

## Current Liabilities | 5.3 m | 7.2 m | 4.8 m | 5.2 m | 6.9 m | 8.4 m | 10.1 m | 8.4 m | 11.6 m |

## Additional Paid-in Capital | 169.5 m | 169.9 m | 191.7 m | 192.6 m | 193.6 m | 233 m | 234 m | 234.9 m | 236.6 m |

## Retained Earnings | (121.2 m) | (127.5 m) | (142.9 m) | (151.4 m) | (160.8 m) | (172 m) | (180.5 m) | (188.3 m) | (201 m) |

## Total Equity | 48.8 m | 41.2 m | 32.7 m | 61 m | 53.5 m | 46.7 m | 35.6 m | ||

## Financial Leverage | 1.4 x | 1.5 x | 1.7 x | 1.3 x | 1.4 x | 1.4 x | 1.6 x |

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Net Income | (16.1 m) | (30.3 m) | (28.7 m) |

## Depreciation and Amortization | 12.6 k | 18 k | 19 k |

## Inventories | (2.3 m) | (1.2 m) | 922 k |

## Accounts Payable | 2.6 m | 1.3 m | 362 k |

## Cash From Operating Activities | (14.5 m) | (25.5 m) | (23.3 m) |

## Purchases of PP&E | (95.7 k) | (290 k) | (31 k) |

## Cash From Investing Activities | (95.7 k) | (290 k) | (31 k) |

## Cash From Financing Activities | 52.7 m | 20 m | 37.7 m |

## Interest Paid | 1.4 m | 1.5 m | 1.5 m |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (2.9 m) | (9.2 m) | (8.5 m) | (17 m) | (26.4 m) | (7.3 m) | (15.7 m) | (23.5 m) | (7.5 m) |

## Depreciation and Amortization | 5 k | 7.7 k | 5 k | 10.1 k | 14.3 k | 4 k | 9 k | 14 k | 5 k |

## Accounts Payable | 1.6 m | 2.2 m | 724.3 k | 1.2 m | 3 m | (771 k) | (768 k) | (648 k) | 348 k |

## Cash From Operating Activities | (5.6 m) | (13.2 m) | (20.4 m) | (6.7 m) | (13 m) | (20.4 m) | (6 m) | ||

## Purchases of PP&E | (6.7 k) | (42.3 k) | (188.6 k) | (274.1 k) | (288.4 k) | (2 k) | (20 k) | (25 k) | (5 k) |

## Cash From Investing Activities | (6.7 k) | (42.3 k) | (188.6 k) | (274.1 k) | (288.4 k) | (2 k) | (20 k) | (25 k) | (5 k) |

## Long-term Borrowings | (15.8 m) | (15.8 m) | (15.8 m) | (993 k) | |||||

## Cash From Financing Activities | 52.6 m | 52.6 m | 19.5 m | 19.7 m | 19.9 m | 37.8 m | 37.8 m | 37.7 m | (993 k) |

## Interest Paid | 690 k | 1 m | 339.3 k | 718.8 k | 1.1 m | 375 k | 755 k | 1.1 m | 368 k |

Y, 2017 | |
---|---|

## Financial Leverage | 1.6 x |